Christopher Connolley, MD
Gastroenterology · Winston Salem, NCNPI 1396702767
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,200 of the $4,828 with a category attached, or 66.3%. AbbVie accounts for 77.3% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $3,556 and has fallen 92.0% since, to $286 in 2025.
Across 84 payments — averaging $57.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Fujifilm Healthcare Americas Corporation$241
- Pfizer$218
- Takeda Pharmaceuticals U.S.A., Inc.$84
- Medtronic$71
- QOL Medical, LLC$67
- plus $415 from 13 others
Across 17 payments — averaging $4431.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$35K
- Janssen Research & Development, LLC$25K
- Bausch Health US, LLC$15K
What the payments were for
- Speaking & faculty fees$3,20066%
- Food & beverage$1,38729%
- Gifts$1503%
- Other$912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $3,732 |
| Fujifilm Healthcare Americas Corporation | 6 | $241 |
| Pfizer | 13 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $84 |
| Medtronic | 1 | $71 |
| QOL Medical, LLC | 5 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Madrigal Pharmaceuticals | 2 | $48 |
| Johnson & Johnson | 2 | $47 |
| Merck | 3 | $44 |
| Gilead | 2 | $37 |
| UCB, Inc. | 1 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Ferring Pharmaceuticals Inc. | 2 | $30 |
| Bristol Myers Squibb | 2 | $26 |
| Sanofi | 1 | $20 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Shionogi Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$1,800
- VIBERZI$1,400
- ESD - Core Endoscopy$148
How this compares
$4,828 in reported general payments places this provider in the 65th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 41 | $1,105,264 |
| LinzessLinaclotide | 110 | $69,026 |
| CreonLipase/Protease/Amylase | 14 | $35,030 |
| DexilantDexlansoprazole | 12 | $9,773 |
| Dexlansoprazole DrDexlansoprazole | 16 | $7,080 |
| TrulancePlecanatide | 15 | $6,608 |
| Ursodiol | 40 | $5,341 |
| MotegrityPrucalopride Succinate | 11 | $5,318 |
| Omeprazole | 264 | $4,880 |
| Dicyclomine Hcl | 120 | $3,174 |
| Pantoprazole Sodium | 227 | $2,718 |
| Lansoprazole | 26 | $2,665 |
| Lubiprostone | 18 | $2,548 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 15 | $2,503 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 33 | $2,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $47 | $1,105,26441 claims |
| AbbVieLinzess, Creon | $3,732 | $104,056124 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant, Motegrity | $84 | $15,09123 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $56 | $6,60815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 610 gastroenterology providers in North Carolina.
Other gastroenterology in Winston Salem
- Andrew StormWinston Salem$426K
- Kenneth KochWinston Salem$74K
- Herbert BonkovskyWinston Salem$57K
- Girish MishraWinston Salem$56K
- Richard BloomfeldWinston Salem$27K
- Stephen DealCharlotte$945K
- Fred FowlerCharlotte$932K
- Paul WatkinsChapel Hill$876K
- Nilesh LodhiaCharlotte$735K
- Evan DellonChapel Hill$431K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.